Mukka Proteins Limited (NSE: MUKKA) announced its financial results for the second quarter and half year ended September 30, 2026, showcasing a robust performance. The company reported a 108.06% year-on-year growth in revenue, reaching ₹ 5,088.70 Mn, and a significant 157.51% year-on-year increase in PAT, standing at ₹ 177.27 Mn. These impressive figures highlight Mukka Proteins’ strong execution and growth trajectory.

Consolidated Financial Performance

The consolidated revenue for Q2 FY27 was ₹ 5,088.70 Mn, compared to ₹ 4,896.54 Mn in Q1 FY27 and ₹ 2,445.81 Mn in Q2 FY26. The PAT for the quarter stood at ₹ 177.27 Mn, up from ₹ 68.84 Mn in Q2 FY26. The EBITDA increased to ₹ 501.18 Mn, marking a 90.73% year-on-year increase. The EBITDA margin stood at 9.85%, down slightly from 10.74% in the same quarter last year.

Standalone Financial Performance

On a standalone basis, revenue for Q2 FY27 was ₹ 4,115.42 Mn, reflecting an 85.15% year-on-year growth. The PAT rose to ₹ 106.99 Mn from ₹ 36.10 Mn in Q2 FY26. The EBITDA increased to ₹ 357.53 Mn, up 84.41% year-on-year. The PAT margin expanded to 2.60%, up from 1.62% in the same quarter last year.

The growth was supported by strong export demand, improved realizations, and favorable industry dynamics amid global fishmeal supply constraints. However, geopolitical disruptions and supply-chain constraints resulted in the execution of certain shipments being deferred to October 2026.

Mukka Proteins’ capacity expansion, including the commencement of commercial production at the Oman facility, has increased the Group’s overall production capacity and strengthened its manufacturing presence in the Middle East. The U.S. FDA facility registration and USDA NOP Inputs Attestation for Eco Sphere Organic Fertilizer are expected to support product acceptance in organic-farming markets, including the United States.

Looking ahead, Mukka Proteins aims to ramp up operations at the Al Juba facility, execute deferred shipments, deepen market access, and improve operating efficiencies across the Group.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Mukka Proteins Limited

Mukka Proteins Limited belongs to the Consumer Defensive › Packaged Foods sector. Here’s a quick read on where the business and the stock stand today.

Mukka posts a 22.0% three-month gain, but softens in the last few weeks. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. The PEG of 2.12 makes it expensive versus peers. The premium needs earnings to catch up quickly. The stock gives back 5.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 22.0% in three months on 6.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Mukka Proteins Limited.

Jaro Institute of Technology Management and Research Limited (JARO) showcased a robust financial performance in H1 FY27, with a 21% year-on-year (YoY) increase in Profit After Tax (PAT) and a 15% rise in total income. The company’s sustained revenue growth, improved profitability, and strategic expansion of academic partnerships and future-ready program portfolios underpinned this performance.

Strong Earnings Growth

In Q2 FY27, JARO’s PAT rose 9% YoY to Rs. 1,854 lakh, reflecting stronger earnings growth. The company’s PAT margin remained healthy at approximately 21% of revenue from operations. This robust performance continued in H1 FY27, with PAT growing 21% to Rs. 2,971 lakh, outperforming revenue growth.

Operational Traction and Strategic Expansion

JARO witnessed encouraging operational traction, with learner volumes registering 7% YoY growth and gross bookings growing 13% to Rs. 22,710 lakh during Q2 FY27. The company expanded its academic ecosystem through new partnerships with prestigious institutions, including IIT Kharagpur and CHRIST (Deemed to be University), Bengaluru. These strategic partnerships aim to develop a diversified, industry-relevant learning portfolio.

Future-Ready Initiatives

JARO introduced its #GrowWithJaro initiative in association with IIT Madras Pravartak to democratise AI literacy and enable mass upskilling across India. This initiative aims to bridge the gap between AI adoption and practical AI capabilities by making AI-focused education more accessible and affordable. As JARO enters the second half of FY27, it remains focused on strengthening learner engagement and scaling its future-ready program portfolio.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Jaro Institute of Technology Management and Research Limited

Jaro Institute of Technology Management and Research Limited belongs to the Consumer Defensive › Education & Training Services sector. Here’s a quick read on where the business and the stock stand today.

Jaro drops 17.1% over three months and trades near its 52-week lows. The PEG of 0.24 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 30.9% and profits at 65.6% CAGR. Both numbers are exceptional. The stock sits at 7% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 30.9% and profits at 65.6% CAGR, with D/E of 0.37. Meanwhile, the stock dips 17.1% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Jaro Institute of Technology Management and Research Limited.

Godrej Agrovet Limited (GODREJAGRO) today announced its financial results for the second quarter and first half of the financial year 2027, ended September 30, 2026. The company delivered strong double-digit revenue growth and earnings resilience amid a challenging operating environment. In Q2 FY27, revenue grew 17% to ₹2,995 crore, while Profit after Tax (PAT) surged 22% to ₹103 crore.

Q2 Financial Highlights

The company’s performance was led by a solid contribution from the Animal Nutrition and Oil Palm segments. Animal Nutrition saw a revenue growth of 14% driven by higher realizations and volume growth. Oil Palm segment revenue increased by 28%, supported by higher CPO and PKO realizations. Despite headwinds from input cost inflation and El Niño, the company managed to maintain a flat EBITDA of ₹222 crore. Profit before Tax (PBT) increased by 5% to ₹131 crore.

H1 FY27 Performance

In the first half of FY27, revenue grew 13% to ₹5,847 crore, led by Oil Palm and Animal Nutrition segments. Although EBITDA, PBT, and PAT declined by 5%, 4%, and 1% respectively, the company’s strategic initiatives in premiumizing the portfolio and focusing on scalable segments contributed to overall performance. The Managing Director, Mr. Sunil Kataria, highlighted the company’s resilience and commitment to advancing its strategic transformation.

As we enter the second half of FY27, Godrej Agrovet remains focused on its strategic transformation and creating sustainable long-term value for all stakeholders.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Godrej Agrovet Limited

Godrej Agrovet Limited belongs to the Consumer Defensive › Packaged Foods sector. Here’s a quick read on where the business and the stock stand today.

Godrej posts a 11.5% three-month gain, but softens in the last few weeks. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. The PEG of 1.70 limits the upside. The stock does not come cheap. The stock gives back 2.2% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 11.5% in three months on 3.1% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Godrej Agrovet Limited.